Alternative Splicing in Breast Cancer and the Potential Development of Therapeutic Tools
Open Access
- 5 October 2017
- Vol. 8 (10), 217
- https://doi.org/10.3390/genes8100217
Abstract
Alternative splicing is a key molecular mechanism now considered as a hallmark of cancer that has been associated with the expression of distinct isoforms during the onset and progression of the disease. The leading cause of cancer-related deaths in women worldwide is breast cancer, and even when the role of alternative splicing in this type of cancer has been established, the function of this mechanism in breast cancer biology is not completely decoded. In order to gain a comprehensive view of the role of alternative splicing in breast cancer biology and development, we summarize here recent findings regarding alternative splicing events that have been well documented for breast cancer evolution, considering its prognostic and therapeutic value. Moreover, we analyze how the response to endocrine and chemical therapies could be affected due to alternative splicing and differential expression of variant isoforms. With all this knowledge, it becomes clear that targeting alternative splicing represents an innovative approach for breast cancer therapeutics and the information derived from current studies could guide clinical decisions with a direct impact in the clinical advances for breast cancer patients nowadays.This publication has 137 references indexed in Scilit:
- BreastMark: An Integrated Approach to Mining Publicly Available Transcriptomic Datasets Relating to Breast Cancer OutcomeBreast Cancer Research, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- The Alternatively Spliced Acid Box Region Plays a Key Role in FGF Receptor AutoinhibitionStructure, 2012
- New plays in the p53 theaterCurrent Opinion in Genetics & Development, 2011
- Is Breast Cancer the Same Disease in Asian and Western Countries?World Journal of Surgery, 2010
- Expansion of the eukaryotic proteome by alternative splicingNature, 2010
- Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancerCancer, 2008
- Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer StudyJAMA, 2006
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in EuropeInternational Journal of Cancer, 2004